Durvalumab plus tarlatamab significantly improved OS and PFS vs durvalumab alone as maintenance in extensive-stage SCLC, per topline phase 3 data.
|Videos|April 28, 2017
Dr. Bunn on FDA Approval of Brigatinib for Patients With ALK+ NSCLC
Author(s)Paul A. Bunn Jr, MD
Paul A. Bunn Jr, MD, Distinguished Professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer. discusses the FDA approval of brigatinib for the treatment of patients with ALK-positive non–small cell lung cancer (NSCLC).
Advertisement
Paul A. Bunn Jr, MD, Distinguished Professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer. discusses the FDA approval of brigatinib for the treatment of patients with ALK-positive non—small cell lung cancer (NSCLC).
Advertisement
Related to this article
D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.
The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Daraxonrasib produced a 42% overall response rate and 16.0-month median OS in previously treated RAS-mutant NSCLC in a phase 1/2 trial.
Ivonescimab significantly improved OS vs pembrolizumab at a prespecified interim analysis of the HARMONi-2 trial in first-line PD-L1–positive NSCLC.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss optimizing first-line treatment selection and second-line sequencing in EGFR-mutated NSCLC.
During a recent OncLive Peer Exchange, panelists discussed testing strategies, updated data, and treatment sequencing in ROS1+ NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
2
Arlo-Cel Meets ORR End Point in BCMA-Pretreated, Quadruple-Class Exposed R/R Myeloma
3
Camidge and Singhi Highlight the Lung Cancer Abstracts to Watch at WCLC 2026
4
Frontline Mipletamig Triplet Drives Clinical Benefit in TP53-Mutated AML
5